Abstract 1598P
Background
The importance of Hospice & Palliative care for patients with terminal cancer is well established. Although hospice use is increasing, the use of hospice services is still suboptimal. Previous studies reported that surgeons tend to underuse palliative care (PC) consultation. This study aimed to investigate potential variations in referral patterns to the PC team and differences in end-of-life care among specialized physicians in patients with terminal cancer.
Methods
A single-institution retrospective observational study of consecutive PC consultations within a National Cancer Institute-designated cancer center in 2020-2021 was conducted. We categorized specialized physicians into medical oncologists (MO) and non-medical oncologists (NMO), which include hematologists, gastroenterologists, surgical and radiation oncologists.
Results
We analyzed 1710 patients, 1130 were referred from MO and 580 from NMO. Patients in the NMO group had lower levels of prognostic awareness (PA) regarding their terminal cancer status compared to those in MO. 44.7 % of patients in the MO group and 16.2 % of patients in the NMO group had accurate PA (p<0.01). The median survival from a day of PC consultation was 40.7 days for all, 47.3 days for the MO group, and 28 days for NMO group (p = 0.00). The survival time after planning Advance Directives was 100 days for all, significantly longer in the MO group (131.2 vs. 54.9 days, p=0.00). The median time from notification of discontinuation of active cancer treatment to PC consultation was 40 days. The interval to PC consultation was significantly longer in patients referred from the NMO group (92.6 days in the NMO group vs. 13.5 days in the MO group, p=0.00). The rate of discharge to specialized inpatient hospice facilities or home hospice was higher in the MO group. However, the discharge rate to acute-stage hospital, ICU was higher in the NMO group.
Conclusions
There was significant variation in referral patterns to the PC team according to a division of physicians. NMO patients had a lower level of prognostic awareness (PA) compared to MO patients. Late referrals to the PC team were observed in the NMO group. This suggests a need for increased education and training in palliative care for the NMO.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05